Efficacy of dapagliflozin combined with glucagon-like peptide-1 receptor agonists for patients with type 2 diabetes mellitus

HONG Guanyu; JI Chunmin; LIU Jiahe

doi:10.7619/jcmp.20233682

Journal of Clinical Medicine in Practice > 2024 > 28(7): 90-95. > DOI: 10.7619/jcmp.20233682

HONG Guanyu, JI Chunmin, LIU Jiahe. Efficacy of dapagliflozin combined with glucagon-like peptide-1 receptor agonists for patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2024, 28(7): 90-95. DOI: 10.7619/jcmp.20233682

Citation:

PDF (828 KB)

Efficacy of dapagliflozin combined with glucagon-like peptide-1 receptor agonists for patients with type 2 diabetes mellitus

Department of Endocrinology, Quanzhou City Hospital of Traditional Chinese Medicine in Fujian Province, Quanzhou, Fujian, 362000

More Information

Received Date: November 15, 2023
Revised Date: March 05, 2024
Available Online: April 21, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the effects of dapagliflozin combined with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on hemorheology and insulin resistance in patients with type 2 diabetes mellitus.
Methods
A total of 102 patients with type 2 diabetes mellitus in Quanzhou City Hospital of Traditional Chinese Medicine from November 2020 to October 2022 were randomly divided into two groups, with 51 cases in each group. Control group was treated with dapagliflozin, while study group received a combination therapy of dapagliflozin and GLP-1 RAs (liraglutide). The clinical efficacy, blood glucose indicators[fasting blood glucose (FBG), 2-hour postprandial glucose (2 hPG), glycated hemoglobin (HbA1c)], fasting insulin (FINS) and insulin resistance[homeostasis model assessment of insulin resistance (HOMA-IR), homeostasis model assessment of β-cell function (HOMA-β)], lipid indicators[total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-densitylipoprotein cholesterol (LDL-C)], hemorheological indicators[erythrocyte aggregation index (EAI), hematocrit (HCT), erythrocyte deformation index (EDI), plasma viscosity (PV)], and adverse reactions were compared between the two groups.
Results
The total effective rate was 94.12% in the study group, which was significantly higher than 80.39% in the control group (P<0.05). After treatment, FBG, 2 hPG, HbA1c and BMI were significantly lower than those before treatment in both groups, and levels of FBG, 2 hPG and HbA1c in the study group were significantly lower than those in the control group (P<0.05). After treatment, FINS and HOMA-β in the study group were significantly higher than those in the control group, while HOMA-IR was significantly lower than that in the control group (P<0.05). After treatment, HDL-C level was significantly higher than that before treatment in both groups, while TC, TG and LDL-C levels were significantly lower in both groups; additionally, HDL-C level after treatment in the study group was significantly higher than that in the control group, while TC, TG and LDL-C levels were significantly lower than those in the control group (P<0.05). After treatment, EAI, HCT, EDI and PV levels were significantly lower than those before treatment in both groups, and levels of indexes mentioned above in the study group were significantly lower than those in the control group (P<0.05). The total incidence of adverse reactions in the study group was 11.76%, which showed no significant difference when compared to 9.80% in the control group (P>0.05).
Conclusion
The combination therapy of dapagliflozin and GLP-1 RAs (liraglutide) is effective in the treatment of patients with type 2 diabetes mellitus, which can effectively regulate blood glucose and lipid levels, alleviate insulin resistance, and improve hemorheological indicators.
- type 2 diabetes mellitus,
- dapagliflozin,
- glucagon-like peptide-1 receptor agonists,
- hemorheology,
- insulin resistance

FullText(HTML)

References (24)

References

[1]	KAWAI Y, UNEDA K, YAMADA T, et al. Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: a systematic review and network meta-analysis[J]. Diabetes Res Clin Pract, 2022, 183: 109146. doi: 10.1016/j.diabres.2021.109146
[2]	WEI X B, WEI W, DING L L, et al. Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: a network meta-analysis of large randomized trials[J]. Prim Care Diabetes, 2021, 15(2): 208-211. doi: 10.1016/j.pcd.2020.08.017
[3]	ALHINDI Y, AVERY A. The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: a systematic review and network meta-analysis[J]. Contemp Clin Trials Commun, 2022, 28: 100944. doi: 10.1016/j.conctc.2022.100944
[4]	KARAGIANNIS T, AVGERINOS I, LIAKOS A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis[J]. Diabetologia, 2022, 65(8): 1251-1261. doi: 10.1007/s00125-022-05715-4
[5]	何东盈, 刘晓霞, 刘天, 等. 茵陈五苓散联合穴位按摩治疗痰湿型肥胖2型糖尿病的临床疗效观察[J]. 中华中医药学刊, 2022, 40(5): 227-230. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS202205048.htm
[6]	王小华, 陈建平, 陈蓉. 达格列净联合缬沙坦治疗早期糖尿病肾病的临床疗效[J]. 临床合理用药杂志, 2021, 14(30): 8-11, 15. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202130003.htm
[7]	杨祉妍, 杜悦, 王昕宇, 等. GLP-1受体激动剂治疗2型糖尿病合并肾损伤患者的疗效和安全性: 一项Meta分析[J]. 中国医院药学杂志, 2022, 42(18): 1910-1917. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYZ202218011.htm
[8]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 国际内分泌代谢杂志, 2021, 41(5): 482-548. doi: 10.3760/cma.j.cn121383-20210825-08063
[9]	DE BLOCK C E M, DIRINCK E, VERHAEGEN A, et al. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes[J]. Diabetes Obes Metab, 2022, 24(5): 788-805. doi: 10.1111/dom.14640
[10]	李双. GLP-1受体激动剂联合胰岛素泵对2型糖尿病患者胰岛素抵抗的影响[J]. 吉林医学, 2022, 43(4): 1031-1033. doi: 10.3969/j.issn.1004-0412.2022.04.066
[11]	陆延, 滑瑞雪, 孙玲. 胰高血糖素样肽-1受体激动剂对2型糖尿病患者肾脏预后的荟萃分析[J]. 中国中西医结合肾病杂志, 2022, 23(3): 247-251. https://www.cnki.com.cn/Article/CJFDTOTAL-JXSB202203014.htm
[12]	HEERSPINK H J L, JONGS N, CHERTOW G M, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial[J]. Lancet Diabetes Endocrinol, 2021, 9(11): 743-754. doi: 10.1016/S2213-8587(21)00242-4
[13]	JONGS N, GREENE T, CHERTOW G M, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial[J]. Lancet Diabetes Endocrinol, 2021, 9(11): 755-766. doi: 10.1016/S2213-8587(21)00243-6
[14]	CORNELL S. A review of GLP-1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once-weekly agents[J]. J Clin Pharm Ther, 2020, 45(Suppl 1): 17-27.
[15]	NAUCK M A, QUAST D R, WEFERS J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art[J]. Mol Metab, 2021, 46: 101102. doi: 10.1016/j.molmet.2020.101102
[16]	闫坤, 原丽敏, 张培育, 等. PPARα激动剂联合GLP-1 RAs对2型糖尿病患者Omentin-1、Asprosin水平的影响[J]. 广东医学, 2022, 43(1): 90-93. https://www.cnki.com.cn/Article/CJFDTOTAL-GAYX202201018.htm
[17]	赵传志, 陈凤玲. 德谷胰岛素联合GLP-1 RAs对2型糖尿病患者Omentin-1、VaspinRBP4水平的影响[J]. 河北医药, 2022, 44(5): 704-707. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ202205014.htm
[18]	郭晓静, 冯晓荣, 苏佩合. 利拉鲁肽联合甘精胰岛素治疗新诊断2型糖尿病的疗效分析[J]. 实用临床医药杂志, 2018, 22(23): 43-46. doi: 10.7619/jcmp.201823013
[19]	GILBERT M P, PRATLEY R E. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials[J]. Front Endocrinol, 2020, 11: 178.
[20]	YAMADA T, WAKABAYASHI M, BHALLA A, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis[J]. Cardiovasc Diabetol, 2021, 20(1): 14.
[21]	TRUJILLO J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes[J]. J Clin Pharm Ther, 2020, 45(Suppl 1): 43-60.
[22]	CHUBB B, GUPTA P, GUPTA J, et al. Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: systematic review and network meta-analysis[J]. Diabetes Ther, 2021, 12(5): 1325-1339.
[23]	ZHOU J Y, POUDEL A, WELCHKO R, et al. Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways[J]. Eur J Pharmacol, 2019, 861: 172594.
[24]	马刚, 孙家忠. GLP-1 RAs联合恩格列净对2型糖尿病患者的治疗效果及对胰岛素抵抗的影响[J]. 实用医学杂志, 2020, 36(18): 2500-2504. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ202018009.htm

Cited By

Cited by

Periodical cited type(19)

1.	安应飞，张安生，党薇，裴金莹，郭莉. 预成纤维桩在口腔修复患者中的应用效果及对牙周环境、修复成功率的影响. 临床医学研究与实践. 2024(23): 17-20 .
2.	王雪，安民. 纤维桩树脂核冠修复上颌前磨牙缺损临床效果及抗折性能研究. 陕西医学杂志. 2023(02): 180-183 .
3.	李晓红，谌刚龙，巴晓晔. 预成纤维桩在口腔修复中的应用效果及对咀嚼功能、牙周健康的影响. 临床医学研究与实践. 2023(17): 77-81 .
4.	卢勇士. 不同方案治疗前牙残根Ⅴ类缺损的临床疗效观察. 中国现代药物应用. 2023(14): 47-49 .
5.	田东源，李娜，丁丽. 金属桩口腔修复与预成纤维桩口腔修复临床疗效及安全性的对比分析. 贵州医药. 2023(10): 1554-1555 .
6.	王巍，徐小川，詹妮. 不同桩核材料联合氧化锆全瓷冠修复前牙牙体缺损的美学效果对比. 中国美容医学. 2023(12): 128-131 .
7.	刘学军，樊牮，赵雪，付东杰. 预成纤维桩对口腔修复患者牙周指数及MMP水平的影响. 临床口腔医学杂志. 2022(05): 299-302 .
8.	李新玲. 金属桩与预成纤维桩应用于口腔修复对比研究. 黑龙江医药科学. 2022(04): 189-190 .
9.	蔡萍，吴亚娟，张祥. 玻璃纤维桩修复牙体缺损患者的综合效果分析. 中国美容医学. 2022(08): 129-133 .
10.	张昕，潘冬梅，宋丹丹. 预成纤维桩与可塑纤维桩在口腔修复中的应用安全性及有效性比较. 当代医学. 2022(21): 149-151 .
11.	陈冲，热依拉·艾克兰木，冷春涛，郭涛. 即刻种植及残根保存修复治疗前牙残根Ⅴ类缺损的疗效观察. 口腔颌面修复学杂志. 2022(05): 337-341 .
12.	祁东. 预成纤维桩与可塑纤维桩在口腔修复中的疗效及安全性分析. 中国现代药物应用. 2022(24): 67-70 .
13.	罗红涛. 不同口腔修复材料在牙齿缺失患者中的应用分析. 黑龙江医学. 2021(06): 583-585 .
14.	王玫，毛玉虎，钱君荣. 预成纤维桩在口腔修复中的应用进展. 医学综述. 2021(08): 1591-1595 .
15.	张冲. 传统金属桩、预成纤维桩和可塑纤维桩在口腔修复中的临床应用效果研究. 现代医药卫生. 2020(05): 746-748 .
16.	伍思俊，黎日照. 预成纤维桩在口腔修复中的临床效果评价探究. 名医. 2020(12): 32-33 .
17.	南骏翔，葛子. 儿童牙体缺损采取不同的修复方法及疗效分析. 中国继续医学教育. 2020(21): 130-132 .
18.	孟倩，李沙沙. 预成纤维桩或可塑纤维桩在口腔修复中的应用效果探究. 中国实用医药. 2020(32): 82-84 .
19.	曲波. 预成纤维桩用于老年牙体缺损患者口腔修复临床效果评估. 中国药物与临床. 2020(22): 3760-3762 .

Other cited types(1)

Get Citation

PDF

XML

Article views (112) PDF downloads (4) Cited by(20)

Turn off MathJax

Article Contents

Abstract

References

Efficacy of dapagliflozin combined with glucagon-like peptide-1 receptor agonists for patients with type 2 diabetes mellitus

Abstract

References

Cited by

Periodical cited type(19)

Other cited types(1)

Catalog

Export File

Citation

Format

Content